-
-
Overview
-
Please contact us at for specific academic pricing.
Background
Tebipenem is an orally available carbapenem antibiotic. Tebipenem is active against a panel of clinical isolates from a variety of bacterial species (MIC50s ≤ 0.0039 ~ 8 µg/ml), including methicillin-resistant strains of Staphylococcus aureus (S. aureus) and Staphylococcus epidermidis (S. epidermidis), as well as penicillin-resistant Streptococcus pneumoniae (S. pneumonia). Tebipenem also inhibits β-lactamase in a time- and concentration-dependent manner. Tebipenem pivoxil, a derivative of tebipenem, has been under development as the first orally available carbapenem antibiotic for the treatment of respiratory and otolaryngological infections caused by drug-resistant S. pneumonia in pediatric patients.
1. Hazra S, Xu H, Blanchard JS. Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis. Biochemistry, 2014, 53(22): 3671-3678.
2. Fujimoto K, Takemoto K, Hatano K, et al. Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals. Antimicrobial Agents and Chemotherapy, 2013, 57(2): 697-707.
-
- Properties
-
Overview